Although Medtronic has lost share in deep brain stimulation (DBS) over the last several years, the Company upped its game recently with the EU launch of its new Percept PC Neurostimulator with BrainSense technology, which received CE Mark in January 2020. Percept is a primary cell DBS device that can send and record brain signals while delivering therapy to patients for the treatment of symptoms associated with Parkinson’s disease, essential tremor, primary dystonic, epilepsy and obsessive-compulsive disorder. Although Percept is currently available in the EU for open-loop sensing, the device is closed-loop capable, and Medtronic plans to conduct additional research in closed-loop DBS in hopes of eventually gaining regulatory approval for an Adaptive DBS system.
To find out more about Percept DBS, BrainSense technology and what’s next for Medtronic’s Brain Modulation Business, click on the following video to listen to SmartTRAK’s interview with Mike Daly, Vice President and General Manager of the Brain Modulation Business within Medtronic. A transcript of the interview is also provided below.